LMT Lombard Med.Tec

    RNS Number : 9528I
  Lombard Medical Technologies PLC
  26 November 2008
   

    Press Information 

    Lombard Medical Technologies PLC
    ("Lombard Medical" or "the Company")


    Growing positive clinical experience of Aorfix* across the world

    -Approval received for Aorfix* in Russia -

    London, UK, 26 November 2008 - Lombard Medical Technologies PLC ("Lombard Medical" or "the Company"), the specialist medical device
company, is pleased to announce that its lead product, Aorfix* for the treatment of abdominal aortic aneurysms ("AAAs"), has received
positive reviews by industry leaders at this year's Veith Symposium held in New York last week.

    Professor Brian Hopkinson described the breadth and depth of experience that has been gained with the Aorfix* implant worldwide in his
symposium paper presented at Veith. He showed recent X-ray images of a patient who has been successfully treated for an angled and tortuous
AAA, six years after receiving implantation of the Aorfix* device in 2002.

    Hopkinson went on to describe Lombard Medical's multi-centre European study, performed in Greece, Poland and Austria, which began in
2003 and is now providing data 4 years post-implantation. The study shows that Aorfix* provides significant annual shrinkage (8% to 16%) of
the aneurysm sac with no migration of the device. 

    Commenting on Aorfix*, Professor Hopkinson said: 
    "With more than six years' implantation experience behind the product, and positive feedback across a wide spectrum of countries and
patients, Aorfix* is increasingly the treatment of choice for specialists in this field. Extreme angulation is handled with results equally
as good as more standard anatomy, leaving little doubt about the product's ability to successfully treat both standard and severely angled
AAAs."

    Professor Hopkinson also drew attention to the results gained from the Company's Retrospective Aorfix* Data Retrieval (''RADAR'')
registry of cases.  The registry allows any Aorfix* surgical team around the world voluntarily to record the outcomes of cases, thereby
collecting a broad mix of challenging patients and surgical techniques. Hopkinson presented 12 months' follow-up data on 67 patients from 16
hospitals in 7 European countries. The aneurysms treated were both larger in diameter than usual and more angulated. Sac reduction of 9% was
recorded after 1 year implantation which is similar to the results obtained in the first clinical trial of Aorfix*.

    The Company also today announces that Aorfix* has been granted approval for use in Russia, adding to the growing positive clinical
experience of Aorfix* across the world. Russia is a large and growing market, presenting a significant sales opportunity for the Company. To
date Aorfix* has been successfully implanted into two patients and a further 15 implants are expected before the end of the year.

    Commenting on Aorfix*, Brian Howlett, Chief Executive of Lombard Medical, said: 
    "We are extremely pleased with the feedback received on Aorfix* at the Veith Symposium, confirming the widely held view amongst
clinicians that Aorfix* is a versatile device which can be deployed in both routine and complex anatomies. It is also pleasing to obtain
approval for Aorfix* in Russia which is a rapidly growing market and will significantly increase the sales potential for Aorfix*."


    Enquiries:

 Lombard Medical Technologies PLC                           Tel: 01235 750 800
 Simon Neathercoat, Non-executive Chairman
 Brian Howlett, Chief Executive Officer 
 Tim Hall, Finance Director

 Financial Dynamics                                         Tel: 020 7831 3113
 David Yates / Susan Quigley

 Nomura Code
 Juliet Thompson / Richard Potts                            Tel: 020 7776 1200

    Notes to editors
    About Lombard Medical
    Lombard Medical Technologies PLC is a medical devices group developing stent grafts and other medical products for use in the treatment
of vascular disease. The Company's lead product, Aorfix*, is an endovascular stent graft for the treatment of abdominal aortic aneurysms
(AAAs), a balloon-like enlargement of the aorta which, if untreated, may rupture and cause death. Approximately 1.7 million people have AAAs
in the US where it is the 13th largest cause of death. The market for endovascular stent grafts for the treatment of AAA is currently worth
over $600 million and is expected to grow to around a $1 billion by 2010. Aorfix* is currently being commercialised in the EU, with a
pivotal clinical trial ongoing in the USA.  

    The Company's Polymer Coatings Division has developed a novel hydrophilic surface treatment to reduce friction on catheters called
GlideMax*, which is available for licensing, and is using its polymer coating technology in a number of research collaborations developing
novel products for the $5 billion drug-eluting stent market.

    The Company headquartered in Oxfordshire, with operations in Yorkshire, Ayrshire and Boston, USA.
    Further background on the Company can be found at www.lombardmedical.com. 


This information is provided by RNS
The company news service from the London Stock Exchange
 
  END 
 
MSCEAXFKAEKPFEE

Lombard Medical Technologies (LSE:LMT)
Historical Stock Chart
From Jun 2024 to Jul 2024

Lombard Medical Technologies (LSE:LMT)
Historical Stock Chart
From Jul 2023 to Jul 2024